The LiMA Study is a multi-site clinical trial investigating whether a stimulant medication, lisdexamfetamine, is a safe and effective treatment for methamphetamine dependence.
The study is a randomised double-blind placebo-controlled study where one group of participants will receive either lisdexamfetamine or a placebo medication, in addition to counselling (CBT). Participants are given the medication for 15 weeks and interviews are held with researchers unaware of their group allocation. The two groups will be compared on methamphetamine use, as well as other measures of change in substance use, health and wellbeing. It is anticipated that the findings will contribute to evidence for the future use of lisdexamfetamine in the treatment of methamphetamine dependence.
Lead investigator A/Prof Nadine Ezard from St Vincent’s Hospital Sydney discusses the trial.
Turning Point team
Dr Shalini Arunogiri, Professor Dan Lubman, Dr Daniel Pham, Dr Noel Plumley, Ms Temika Mu, Ms Davinia Rizzo, and Ms Michelle Sharkey.
Associate Professor Nadine Ezard (St Vincent’s Hospital, Sydney), Associate Professor Robert Ali (University of Adelaide), Professor Adrian Dunlop (Hunter New England Local Health District Drug and Alcohol Clinical Services), Professor Nicholas Lintzeris (South East Sydney Local Health District), Professor Jason White (University of South Australia), Associate Professor Rebecca McKetin (National Drug and Alcohol Research Centre), Associate Professor Raimondo Bruno (University of Tasmania), Professor Andrew Carr (St Vincent’s Hospital, Sydney), Professor Andrew Dawson (University of Sydney), Dr Anthony Gill (St Vincent’s Hospital, Sydney), Dr Craig Rogers (St Vincent’s Hospital, Sydney), Associate Professor James Ward (South Australian Health and Medical Research Institute), Dr Mark Montebello (Northern Sydney Local Health District), Professor Michael Farrell (National Drug and Alcohol Research Centre), Dr Willy Liaw (Drug and Alcohol Research Centre), Dr Robert Graham (Western Sydney Local Health District, and Professor Paul Haber (Royal Prince Alfred Hospital).
Learn more about this project
The trial is registered by the Australian New Zealand Clinical Trials Registry (ANZCTR). (#12617000657325)